TreatER webcast seminar – World’s first clinical trial with CDNF: Aiming for a breakthrough in Parkinson’s

  1. Welcome and opening words. Henri Huttunen, Chief Scientific Officer, Herantis Pharma Plc    Video (4:12 min)
  2. Neurotrophic Factors in clinical trials – Brief look to the recent past, present and years to come. Mart Saarma, Professor, Institute of Biotechnology, University of Helsinki     Video (17:46 min)    Slides (pdf)
  3. Cerebral Dopamine Neurotrophic Factor (CDNF) Potential in prevention of dopamine neuron degeneration and stimulation ofneuron regeneration. Henri Huttunen, Chief Scientific Officer, Herantis Pharma Plc     Video (21:23 min)    Slides (pdf)
  4. First break with 10 min exercise. Josefa DomingosSpecialist Physiotherapist & EPDA Board Member     Video (9:26 min)
  5. CDNF in the first-in-human clinical trial (Safety) –12-month clinical data on the monthly infusions of CDNF directly into a targeted area of the brain of people living with Parkinson’s. Magnus Sjögren, Chief Medical Officer, Herantis Pharma Plc    Video (24:18 min)    Slides (pdf)
  6. CDNF in the first-in-human clinical trial (Efficacy) –12-month clinical data on the monthly infusions of CDNF directly into a targeted area of the brain of people living with Parkinson’s. Per Svenningsson, Principal Investigator, Karolinska University Hospital     Video (23:05 min)     Slides (pdf)
  7. Second break with 10 min exercise. Josefa DomingosSpecialist Physiotherapist & EPDA Board Member     Video (9:11 min)
  8. Clinical data on the investigational drug delivery system used for the CDNF infusionJim Baker, Head of QA/RA and Clinical Affairs, Healthcare Division, Renishaw Plc     Video (17:30 min)     Slides (pdf)
  9. Panel discussion on CDNF development for Parkinson’s disease 
    • Per Svenningsson, Professor, Principal Investigator, Karolinska University Hospital
    • Håkan Widner, Professor, Department of Neurology, Skåne University Hospital
    • Filip Scheperjans, Adjunct Professor of Neurology, Helsinki University Hospital
    • Juha Rinne, Professor, Turku PET Centre
    • Göran Lind, Neurosurgeon, Karolinska University Hospital
    • Paul Skinner, General Manager, Renishaw Neuro Solutions Ltd
    • Craig Cook, CEO, Herantis Pharma Plc
    • Alan Whone, Consultant Senior Lecturer in Movement Disorder, University of Bristol    Video (48:16 min)